Cybin outlines upcoming priorities and milestones for its clinical development programs

Toronto--( business wire )--cybin inc. (neo:cybn) (nyse american: cybn) (cybin or the company), a biopharmaceutical company focused on progressing psychedelics to therapeutics® today outlined its upcoming priorities and near-term milestones that support the development of its cyb003 and cyb004 clinical programs aimed at addressing multiple mental health conditions.
CYBN Ratings Summary
CYBN Quant Ranking